Vanderbilt Vaccine Center

The Vanderbilt Vaccine Center will host a campus-wide presentation by Mark Esser, AstraZeneca vice president and head of microbial sciences, about Evusheld, an antibody combination that combats SARS-CoV-2 developed at Vanderbilt University Medical Center. The talk will be on Thursday, Nov. 17, at 10 a.m. in Light Hall, Room 202. Read More

A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age. Read More

Vanderbilt's James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization. Read More

Dr. James Crowe, Robert Carnahan and their colleagues in the Vanderbilt Vaccine Center won the Gold medal in the 2022 R&D 100 awards for their discovery and development of long-acting antibodies that protect against COVID-19. The discovery of these antibodies has led to the development of Evusheld, pre-exposure therapy to prevent COVID-19 for adults and children over 12 with compromised immune systems or a history of severe adverse reactions to a COVID-19 vaccine. Read More

Vanderbilt's James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19. Read More

Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19. Read More

The U.S. Food and Drug Administration granted emergency use authorization Dec. 8 to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination that protects against COVID-19, discovered last year at Vanderbilt University Medical Center. Read More

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant. Read More

A monoclonal antibody cocktail against the COVID-19 virus discovered at VUMC is the first non-vaccine modified to demonstrate the prevention of COVID-19 in a clinical trial of more than 5,000 participants. The antibody treatment could afford up to 12 months of protection from COVID-19, and preliminary laboratory findings also suggest that it can neutralize the delta variant. Read More

Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential. Read More

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development. Read More

Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus. Read More

The remarkable success of the COVID-19 vaccines began in a Vanderbilt lab decades ago, with the groundbreaking research of alumnus Dr. Barney Graham. Read More

Moderna, remdesivir, AstraZeneca. VUMC’s experts have played an integral role in the development of these marquee COVID-19 therapeutics behind the scenes.  Read More

The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections. Read More

James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award. Read More

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19. Read More

To keep pace with Vanderbilt researchers developing COVID-19 solutions, the Center for Technology Transfer & Commercialization has facilitated three license agreements, 11 patent applications and 43 material transfer agreements in record time. Read More

Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection. Read More

From the front lines of patient care to collaborating with scientists across the globe searching for treatments and vaccines, Vanderbilt University Medical Center and Vanderbilt University researchers have been working for months to combat the COVID-19 pandemic. Read More